Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2010 - 2026)

Jazz Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at $331.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 20.41% year-over-year to $331.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 21.87% YoY), and the FY2025 full-year result was $1.3 billion, down 7.08% from the prior year.
• Free Cash Flow for Q1 2026 stood at $331.0 million, down from $345.8 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.3 billion in Q3 2025, with the low at -$755.3 million in Q2 2025.
• Average Free Cash Flow over 5 years is $313.8 million, with a median of $324.3 million recorded in 2024.
• Year-over-year, Free Cash Flow surged 742.36% in 2022 and sank 332.93% in 2025.
• Tracing JAZZ's Free Cash Flow over 5 years: stood at $332.6 million in 2022, then tumbled by 52.72% to $157.2 million in 2023, then surged by 153.49% to $398.6 million in 2024, then fell by 13.24% to $345.8 million in 2025, then dropped by 4.28% to $331.0 million in 2026.
• The last three Free Cash Flow figures came in at $331.0 million (Q1 2026), $345.8 million (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison